

Press release 2024-09-17

Zeqmelit® Launched in Norway and Finland

AcuCort's launch of Zeqmelit® is proceeding according to the previously communicated plan. At the beginning of September, the medication became available in Swedish pharmacies, and as of September 15, Zeqmelit® is also available in pharmacies in Norway and Finland.

AcuCort had previously communicated that the launch of Zeqmelit® in Norway and Finland would occur shortly after the product's launch in Sweden. Zeqmelit® was launched in Sweden on September 2, and as of September 15, the medication is available in pharmacies in Norway and Finland.

– The launch of Zeqmelit® is progressing as planned, and we have received very positive feedback from both doctors and patients since the product was introduced to the market. Another important milestone has now been achieved with the international expansion brought by the launch in Norway and Finland. Doctors in three Nordic countries can now prescribe Zeqmelit®, and allergy patients can then collect the product at pharmacies, says AcuCort's CEO, Jonas Jönmark.

For further information:

Jonas Jönmark, vd, AcuCort AB

Tel: +46 70 365 5400

Email: jonas.jonmark@acucort.se

About AcuCort AB (publ)

AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.